期刊文献+

^(131)I标记单克隆抗体C50在胃癌放射免疫导向手术中的应用 被引量:1

^(131)I labeled monoclonal antibody C50 in radioimmunoguided surgery in gastricarcinoma
下载PDF
导出
摘要 目的:探讨采用131I标记的癌胚抗原C50单克隆抗体在胃癌放射免疫导向手术(RIGS)中的应用价值。方法:胃癌患者22例术前通过胃镜直视下癌周粘膜下注射131I标记单克隆抗体C50(131I-C50mAb)进行放射免疫导向手术,术中取得组织标本离体测量其重量及γ计数,计算每克靶组织(T)和对照本底组织(NT)放射性计数比值(T/NT)。结果:胃镜直视下癌周粘膜下注射131I-C50mAb可有效区分组织有无癌浸润,分别选用T/NT界值8.0与9.0后判断胃壁肿瘤浸润、淋巴结转移的准确率分别为87.3%和92.6%。结论:C50可作为胃癌放射免疫导向手术的导向单克隆抗体,可为进一步使用手持式γ探测仪进行术中探测提供相应依据。 Objective: To investigate the value of ^131I labeled monoclonal antibody(MAb)C50 in radioimmunoguided surgery (RIGS) of gastricarcinoma, Methods : A clinical trial of radioimmunoguided surgery (RIGS) was performed on 22 cases with tissue-proved gastricarcinoma in this study. Before operation subrnucosal was taken injection via endoscope with ^131I labeled monoclonal antibody (MAb) C50 was giren; in the operation get tissue specimen to measure their weight and count; then target sites (T) and normal tissues (T/NT)were calculated. Results: Submucosal injection via endoscope using ^131I labeled monoclonal antibody(MAb)C50 can detect tumor infiltrated tissues effectively. For the detection of metastatic lymph nodes,the accuracy rate of RIGS was 92.6% (83/90) with the ratio of T/NT as 8.0. The accuracy rate in detecting tumor infiltration of gastric wall was 87.3% (19/22) with the with the ratio of T/NT as 9.0. Conclusion: C50 can act as monoclonal antibody for the RIGS and provide a basis for using hand held gamma probe to detect in the operation.
出处 《陕西医学杂志》 CAS 北大核心 2005年第10期1199-1201,共3页 Shaanxi Medical Journal
  • 相关文献

参考文献6

二级参考文献8

共引文献11

同被引文献29

  • 1傅相平,李安民,张志文,闫润民,易林华,刘爱军.^(131)I-肿瘤细胞核人鼠嵌合单抗脑胶质瘤瘤内放免治疗研究[J].中华实验外科杂志,2005,22(1):102-103. 被引量:12
  • 2许国辉,张智慧,李政文,文华长,胡大武,段天红,文永君,吴辉,杨承莲,曹蓉.^(131)I肝癌单抗片段HAb18F(ab)_2灌注治疗原发性肝癌的临床研究[J].介入放射学杂志,2005,14(6):596-598. 被引量:10
  • 3刘黎,李少林.^(131)I-2F7抗体在荷小细胞肺癌裸鼠体内分布及其对肿瘤的生长抑制作用[J].中华核医学杂志,2006,26(6):357-360. 被引量:7
  • 4李冕,田野苹,孙卫民.肺癌的抗体治疗的研究进展[J].中国肿瘤生物治疗杂志,2007,14(3):296-300. 被引量:1
  • 5Palanca-Wessels MC,Press OW.Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.Cancer,2010,116(4 Suppl):1126-1133.
  • 6Goldsmith SJ.Radioimmunotherapy of lymphoma:Bexxar and Zevalin.Semin Nucl Med,2010,40(2):122-135.
  • 7Jacobs SA,Swerdlow SH,Kant J,et al.Phase Ⅱ trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.Clin CancerRes,2008,14(21):7088-7094.
  • 8Schilder R,Molina A,Bartlett N,et al.Follow-up results of a phase Ⅱ study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade,follicular,or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.Cancer Biother Radiopharm,2004,19(4):478-481.
  • 9Nademance A,Forman S,Molina A,et al.A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell trans-plantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.Blood,2005,106(8):2896-2902.
  • 10Gibson AD.Updated results of a phase Ⅲ trial comparing ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma.Clin Lymphoma,2002,3(2):87-89.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部